首页 > 最新文献

International Forum of Allergy & Rhinology最新文献

英文 中文
Impedance-Controlled Multipoint Radiofrequency Ablation for Chronic Rhinitis: A Randomized Controlled Trial. 阻抗控制多点射频消融治疗慢性鼻炎:一项随机对照试验。
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2026-01-08 DOI: 10.1002/alr.70101
Masayoshi Takashima, Randall A Ow, Richard D Thrasher, Ellen M O'Malley, William R Blythe, Omar G Ahmed

Background: The purpose of this randomized controlled trial (RCT) was to demonstrate that posterior nasal nerve ablation treatment with the NEUROMARK System is superior to a sham control procedure in patients with chronic rhinitis.

Methods: In this prospective, multicenter, single-blinded, superiority RCT, 132 participants were randomized 2:1 to the active treatment arm (88) and sham control arm (44). The primary endpoint was the comparison of the reflective Total Nasal Symptom Score (rTNSS) responder rate between study arms at 90-day follow-up. Secondary efficacy outcomes included postnasal drip, chronic cough, Nasal Obstruction Symptom Evaluation (NOSE), mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), and Patient Health Questionnaire-9 (PHQ-9) (a depression assessment).

Results: The responder rate was significantly higher for the active treatment arm: 73.3% (95% confidence interval [CI], 64.0%-82.7%) compared to the sham control arm: 35.0% (95% CI, 20.2%-49.8%; p < 0.001). The primary endpoint was met, demonstrating the active treatment arm is superior to the sham control arm. The active treatment arm had significantly greater decreases (improvements) in the rTNSS (-4.0 vs. -1.2, p < 0.0001), postnasal drip (-1.1 vs. -0.3, p < 0.001), cough (-0.9 vs. -0.1, p < 0.001), NOSE score (-32.2 vs. -8.0, p < 0.0001), mini-RQLQ (-1.7 vs. -0.5, p < 0.0001), and PHQ-9 (-3.0 vs. -0.7, p = 0.028), compared to the sham control arm. The NOSE responder rate and mini-RQLQ responder rate were significantly higher for the active treatment arm than the sham control arm (p = 0.001 and p < 0.0001, respectively).

Conclusion: Treatment for chronic rhinitis with the NEUROMARK System is superior to sham control.

背景:本随机对照试验(RCT)的目的是证明使用NEUROMARK系统对慢性鼻炎患者进行后鼻神经消融治疗优于假对照治疗。方法:在这项前瞻性、多中心、单盲、优势随机对照试验中,132名参与者按2:1随机分为积极治疗组(88人)和假对照组(44人)。主要终点是在90天随访中比较研究组间的反射性总鼻症状评分(rTNSS)应答率。次要疗效指标包括后滴鼻、慢性咳嗽、鼻塞症状评估(NOSE)、迷你鼻结膜炎生活质量问卷(mini-RQLQ)和患者健康问卷-9 (PHQ-9)(抑郁评估)。结果:积极治疗组的应答率为73.3%(95%可信区间[CI], 64.0% ~ 82.7%),显著高于假对照组的35.0% (95% CI, 20.2% ~ 49.8%; p < 0.001)。主要终点达到,表明积极治疗组优于假对照组。与假对照组相比,积极治疗组在rTNSS (-4.0 vs. -1.2, p < 0.0001)、后滴鼻(-1.1 vs. -0.3, p < 0.001)、咳嗽(-0.9 vs. -0.1, p < 0.001)、NOSE评分(-32.2 vs. -8.0, p < 0.0001)、mini-RQLQ (-1.7 vs. -0.5, p < 0.0001)和PHQ-9 (-3.0 vs. -0.7, p = 0.028)方面的降低(改善)明显更大。积极治疗组的鼻应答率和mini-RQLQ应答率显著高于假对照组(p分别= 0.001和p < 0.0001)。结论:NEUROMARK系统治疗慢性鼻炎优于假对照。
{"title":"Impedance-Controlled Multipoint Radiofrequency Ablation for Chronic Rhinitis: A Randomized Controlled Trial.","authors":"Masayoshi Takashima, Randall A Ow, Richard D Thrasher, Ellen M O'Malley, William R Blythe, Omar G Ahmed","doi":"10.1002/alr.70101","DOIUrl":"https://doi.org/10.1002/alr.70101","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this randomized controlled trial (RCT) was to demonstrate that posterior nasal nerve ablation treatment with the NEUROMARK System is superior to a sham control procedure in patients with chronic rhinitis.</p><p><strong>Methods: </strong>In this prospective, multicenter, single-blinded, superiority RCT, 132 participants were randomized 2:1 to the active treatment arm (88) and sham control arm (44). The primary endpoint was the comparison of the reflective Total Nasal Symptom Score (rTNSS) responder rate between study arms at 90-day follow-up. Secondary efficacy outcomes included postnasal drip, chronic cough, Nasal Obstruction Symptom Evaluation (NOSE), mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), and Patient Health Questionnaire-9 (PHQ-9) (a depression assessment).</p><p><strong>Results: </strong>The responder rate was significantly higher for the active treatment arm: 73.3% (95% confidence interval [CI], 64.0%-82.7%) compared to the sham control arm: 35.0% (95% CI, 20.2%-49.8%; p < 0.001). The primary endpoint was met, demonstrating the active treatment arm is superior to the sham control arm. The active treatment arm had significantly greater decreases (improvements) in the rTNSS (-4.0 vs. -1.2, p < 0.0001), postnasal drip (-1.1 vs. -0.3, p < 0.001), cough (-0.9 vs. -0.1, p < 0.001), NOSE score (-32.2 vs. -8.0, p < 0.0001), mini-RQLQ (-1.7 vs. -0.5, p < 0.0001), and PHQ-9 (-3.0 vs. -0.7, p = 0.028), compared to the sham control arm. The NOSE responder rate and mini-RQLQ responder rate were significantly higher for the active treatment arm than the sham control arm (p = 0.001 and p < 0.0001, respectively).</p><p><strong>Conclusion: </strong>Treatment for chronic rhinitis with the NEUROMARK System is superior to sham control.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145931657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olfactory Function, Caffeine Intake, and Mortality in a Nationally Representative Cohort. 嗅觉功能、咖啡因摄入和死亡率:一项全国代表性队列研究。
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2026-01-08 DOI: 10.1002/alr.70100
Mark Schuweiler, Wassim Najjar, Murugappan Ramanathan, Andrew P Lane, Leila J Mady, Stella E Lee, Nicholas R Rowan
{"title":"Olfactory Function, Caffeine Intake, and Mortality in a Nationally Representative Cohort.","authors":"Mark Schuweiler, Wassim Najjar, Murugappan Ramanathan, Andrew P Lane, Leila J Mady, Stella E Lee, Nicholas R Rowan","doi":"10.1002/alr.70100","DOIUrl":"https://doi.org/10.1002/alr.70100","url":null,"abstract":"","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145931593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological Characteristics of Sinonasal Cancers in Young Adults (<35 years) or Older: A REFCOR Study of 3091 Patients 年轻人(<35岁)或以上鼻窦癌的流行病学特征:一项3091例患者的REFCOR研究
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2026-01-08 DOI: 10.1002/alr.70096
Florent Carsuzaa, Juliette Thariat, Valérie Costes-Martineau, Ludovic de Gabory, Cécile Rumeau, Vincent Patron, Sébastien Vergez, Charles Dupin, Antoine Moya Plana, Justin Michel, Olivier Malard, Xavier Dufour, Benjamin Verillaud, Maxime Fieux, Valentin Favier

Key points

  • Young adults show more advanced sinonasal cancers than older patients.
  • Histologic distribution differs markedly between young and older sinonasal cancers.
  • Overall survival is similar between young adults and older patients despite differences.
重点:年轻人比老年患者表现出更多的晚期鼻窦癌。年轻人和老年人鼻窦癌的组织学分布有显著差异。尽管存在差异,但年轻人和老年患者的总体生存率相似。
{"title":"Epidemiological Characteristics of Sinonasal Cancers in Young Adults (<35 years) or Older: A REFCOR Study of 3091 Patients","authors":"Florent Carsuzaa,&nbsp;Juliette Thariat,&nbsp;Valérie Costes-Martineau,&nbsp;Ludovic de Gabory,&nbsp;Cécile Rumeau,&nbsp;Vincent Patron,&nbsp;Sébastien Vergez,&nbsp;Charles Dupin,&nbsp;Antoine Moya Plana,&nbsp;Justin Michel,&nbsp;Olivier Malard,&nbsp;Xavier Dufour,&nbsp;Benjamin Verillaud,&nbsp;Maxime Fieux,&nbsp;Valentin Favier","doi":"10.1002/alr.70096","DOIUrl":"10.1002/alr.70096","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key points</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>Young adults show more advanced sinonasal cancers than older patients.</li>\u0000 \u0000 <li>Histologic distribution differs markedly between young and older sinonasal cancers.</li>\u0000 \u0000 <li>Overall survival is similar between young adults and older patients despite differences.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 2","pages":"214-217"},"PeriodicalIF":6.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative Management of Patients with Cardiac Comorbidities on Anticoagulation and Antiplatelet Therapy Undergoing Sinonasal Surgery: An American Rhinologic Society Survey and Recommendations 美国鼻科学协会的调查和建议:接受鼻窦手术的心脏合并症患者抗凝和抗血小板治疗的围手术期管理。
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2026-01-06 DOI: 10.1002/alr.70093
Matthew Mendelsohn, Peter Giannaris, Byung J. Park, Aron Z. Pollack, Judd H. Fastenberg, Mark B. Chaskes, Charles C. L. Tong

Key points

  1. Most physicians hold antithrombotic medication prior to surgery, regardless of drug class

  2. Physicians rely on the cardiologist or their own experience for perioperative decision making

  3. There was no consensus on antithrombotic perioperative medication timing across drug classes

大多数医生在手术前都会服用抗血栓药物,而不考虑药物类别。医生依靠心脏病专家或他们自己的经验来做围手术期的决策。
{"title":"Perioperative Management of Patients with Cardiac Comorbidities on Anticoagulation and Antiplatelet Therapy Undergoing Sinonasal Surgery: An American Rhinologic Society Survey and Recommendations","authors":"Matthew Mendelsohn,&nbsp;Peter Giannaris,&nbsp;Byung J. Park,&nbsp;Aron Z. Pollack,&nbsp;Judd H. Fastenberg,&nbsp;Mark B. Chaskes,&nbsp;Charles C. L. Tong","doi":"10.1002/alr.70093","DOIUrl":"10.1002/alr.70093","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key points</h3>\u0000 \u0000 <div>\u0000 <ol>\u0000 \u0000 <li>\u0000 <p>Most physicians hold antithrombotic medication prior to surgery, regardless of drug class</p>\u0000 </li>\u0000 \u0000 <li>\u0000 <p>Physicians rely on the cardiologist or their own experience for perioperative decision making</p>\u0000 </li>\u0000 \u0000 <li>\u0000 <p>There was no consensus on antithrombotic perioperative medication timing across drug classes</p>\u0000 </li>\u0000 </ol>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 2","pages":"209-213"},"PeriodicalIF":6.8,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Dual Setback: Staphylococcus aureus Biofilms From Severe Chronic Rhinosinusitis Show Enhanced Virulence Capacity and Tolerance to Antibiotics. 双重挫折:来自严重慢性鼻窦炎的金黄色葡萄球菌生物膜显示出增强的毒力和对抗生素的耐受性。
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2026-01-06 DOI: 10.1002/alr.70092
Gohar Shaghayegh, Clare Cooksley, Cate Cheney, Sima Kianpour Rad, Beula Subashini Panchatcharam, Emma F Barry, Sholeh Feizi, George Bouras, Alkis James Psaltis, Peter-John Wormald, Sarah Vreugde

Background: Staphylococcus aureus biofilms play a crucial role in chronic rhinosinusitis (CRS), leading to the persistence of symptoms. Severe CRS patients are frequently infected with S. aureus strains that exhibit higher biofilm properties (e.g., biomass, exoprotein production) compared to S. aureus from controls. S. aureus biofilms resist antibiotic treatment; however, the relationship between bacterial biofilm properties, antibiotic susceptibility, and CRS severity has not yet been defined and is the subject of this study.

Methods: S. aureus clinical isolates and reference strains, and matched clinical datasets were collected from CRS patients and controls (n  =  35). Antimicrobial susceptibility of the isolates to clindamycin, mupirocin, clarithromycin, doxycycline, and amoxicillin-clavulanic acid was determined by minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC).

Results: S. aureus MBEC values (n  =  35) were significantly higher (up to 11 times) than the MIC for all five antibiotics (p < 0.001). Among the various antibiotics tested, mupirocin had the strongest antibiofilm activity and amoxicillin-clavulanic acid the weakest: at antibiotic concentrations that are deemed to indicate susceptibility or intermediate resistance when testing in planktonic form, 80% biofilm eradication was reached for all isolates using mupirocin and only 5/35 isolates using amoxicillin-clavulanic acid. The biofilm metabolic activity, biomass, colony-forming units, and exoprotein production were positively correlated with the MBEC values for amoxicillin-clavulanic acid and clarithromycin, but not for the other antibiotics. Lund-Mackay and Lund-Kennedy disease severity scores showed positive correlations with the MBEC values of clarithromycin.

Conclusion: These findings show that whilst severe CRS patients are frequently infected with S. aureus strains that exhibit higher biofilm-mediated virulence, these biofilms are also more difficult to control with standard of care antibiotics. Better personalized therapies are required to manage biofilm-mediated infections in severe CRS patients.

背景:金黄色葡萄球菌生物膜在慢性鼻窦炎(CRS)中起关键作用,导致症状持续。与对照金黄色葡萄球菌相比,严重的CRS患者经常感染表现出更高生物膜特性(例如,生物量、外蛋白产量)的金黄色葡萄球菌菌株。金黄色葡萄球菌生物膜耐抗生素治疗;然而,细菌生物膜特性、抗生素敏感性和CRS严重程度之间的关系尚未明确,这也是本研究的主题。方法:收集CRS患者和对照组(35例)的金黄色葡萄球菌临床分离株、参考菌株和匹配的临床资料。采用最小抑菌浓度(MIC)和最小生物膜根除浓度(MBEC)测定菌株对克林霉素、莫匹罗星、克拉霉素、多西环素和阿莫西林-克拉维酸的敏感性。结果:所有5种抗生素的金黄色葡萄球菌MBEC值(n = 35)显著高于MIC值(高达11倍)(p)。结论:这些发现表明,虽然严重CRS患者经常感染表现出更高生物膜介导毒力的金黄色葡萄球菌菌株,但这些生物膜也更难以用标准护理抗生素控制。需要更好的个性化治疗来管理严重CRS患者的生物膜介导感染。
{"title":"A Dual Setback: Staphylococcus aureus Biofilms From Severe Chronic Rhinosinusitis Show Enhanced Virulence Capacity and Tolerance to Antibiotics.","authors":"Gohar Shaghayegh, Clare Cooksley, Cate Cheney, Sima Kianpour Rad, Beula Subashini Panchatcharam, Emma F Barry, Sholeh Feizi, George Bouras, Alkis James Psaltis, Peter-John Wormald, Sarah Vreugde","doi":"10.1002/alr.70092","DOIUrl":"https://doi.org/10.1002/alr.70092","url":null,"abstract":"<p><strong>Background: </strong>Staphylococcus aureus biofilms play a crucial role in chronic rhinosinusitis (CRS), leading to the persistence of symptoms. Severe CRS patients are frequently infected with S. aureus strains that exhibit higher biofilm properties (e.g., biomass, exoprotein production) compared to S. aureus from controls. S. aureus biofilms resist antibiotic treatment; however, the relationship between bacterial biofilm properties, antibiotic susceptibility, and CRS severity has not yet been defined and is the subject of this study.</p><p><strong>Methods: </strong>S. aureus clinical isolates and reference strains, and matched clinical datasets were collected from CRS patients and controls (n  =  35). Antimicrobial susceptibility of the isolates to clindamycin, mupirocin, clarithromycin, doxycycline, and amoxicillin-clavulanic acid was determined by minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC).</p><p><strong>Results: </strong>S. aureus MBEC values (n  =  35) were significantly higher (up to 11 times) than the MIC for all five antibiotics (p < 0.001). Among the various antibiotics tested, mupirocin had the strongest antibiofilm activity and amoxicillin-clavulanic acid the weakest: at antibiotic concentrations that are deemed to indicate susceptibility or intermediate resistance when testing in planktonic form, 80% biofilm eradication was reached for all isolates using mupirocin and only 5/35 isolates using amoxicillin-clavulanic acid. The biofilm metabolic activity, biomass, colony-forming units, and exoprotein production were positively correlated with the MBEC values for amoxicillin-clavulanic acid and clarithromycin, but not for the other antibiotics. Lund-Mackay and Lund-Kennedy disease severity scores showed positive correlations with the MBEC values of clarithromycin.</p><p><strong>Conclusion: </strong>These findings show that whilst severe CRS patients are frequently infected with S. aureus strains that exhibit higher biofilm-mediated virulence, these biofilms are also more difficult to control with standard of care antibiotics. Better personalized therapies are required to manage biofilm-mediated infections in severe CRS patients.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT). Tezepelumab治疗慢性鼻窦炎伴鼻息肉患者的早期和持续嗅觉改善(WAYPOINT)
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2026-01-06 DOI: 10.1002/alr.70090
Joaquim Mullol, Joseph K Han, Tanya M Laidlaw, Claire Hopkins, Anju T Peters, Oliver Pfaar, Martin Desrosiers, Stella E Lee, Andrew P Lane, Claudia Chen, Yun Chon, Sandhia S Ponnarambil, Andrew Foster, Andrew W Lindsley, Christopher S Ambrose

Background: Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health-related quality of life and posing a safety hazard.

Methods: WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Changes from baseline in biweekly mean Nasal Polyposis Symptom Diary (NPSD) loss of smell item, University of Pennsylvania Smell Identification Test (UPSIT), and 22-item Sino-Nasal Outcome Test (SNOT-22) loss of smell/taste item scores, as well as anosmia (UPSIT score ≤18) prevalence, were assessed over 52 weeks.

Results: Among 408 patients (tezepelumab [n = 203]; placebo [n = 205]), significant improvements with tezepelumab versus placebo in NPSD loss of smell item, UPSIT, and SNOT-22 loss of smell/taste item scores were seen at week 4 (least-squares mean [LSM] treatment difference [95% CI]: -0.36 [-0.46, -0.27]; 6.03 [4.72, 7.34]; and -1.01 [-1.22, -0.80], respectively) and week 52 (-1.01 [-1.18, -0.83]; 9.50 [7.84, 11.16]; and -1.90 [-2.20, -1.61]); all nominal p < 0.0001. Between-treatment differences in daily NPSD loss of smell item score were evident from day 7 (LSM treatment difference: -0.08 [95% CI: -0.15, -0.02]; nominal p < 0.01). Improvements in NPSD loss of smell, UPSIT, and SNOT-22 loss of smell/taste item scores were observed across multiple prespecified subgroups. Anosmia prevalence was lower with tezepelumab than placebo at week 4 (43.0% [n/N = 64/149] vs. 80.3% [n/N = 106/132]) and week 52 (31.5% [n/N = 47/149] vs. 75.8% [n/N = 100/132]).

Conclusions: Tezepelumab provides early and sustained improvements in sense of smell among patients with uncontrolled CRSwNP.

背景:嗅觉丧失是慢性鼻窦炎伴鼻息肉(CRSwNP)的主要症状,影响HRQoL并存在安全隐患。方法:WAYPOINT (NCT04851964)是一项针对未控制的CRSwNP成人患者的3期多中心试验,将患者1:1随机分组,每4周皮下注射tezepelumab 210 mg或安慰剂,持续52周。在52周内评估鼻息肉病症状日记(NPSD)两周平均嗅觉丧失项目、宾夕法尼亚大学嗅觉识别测试(UPSIT)和22项鼻预后测试(SNOT-22)嗅觉/味觉丧失项目得分以及嗅觉缺失(UPSIT评分≤18)发生率的基线变化。结果:在408例患者(tezepelumab [n = 203],安慰剂[n = 205])中,在第4周(最小二乘平均[LSM]治疗差异[95% CI]分别为-0.36[-0.46,-0.27],6.03[4.72,7.34],和-1.01[-1.22,-0.80])和第52周(-1.01[-1.18,-0.83],9.50[7.84,11.16],和-1.90 [-2.20,-1.61]),tezepelumab与安慰剂相比在NPSD嗅觉丧失、UPSIT和SNOT-22嗅觉/味觉丧失得分方面均有显著改善;结论:Tezepelumab为不受控制的CRSwNP患者的嗅觉提供了早期和持续的改善。
{"title":"Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).","authors":"Joaquim Mullol, Joseph K Han, Tanya M Laidlaw, Claire Hopkins, Anju T Peters, Oliver Pfaar, Martin Desrosiers, Stella E Lee, Andrew P Lane, Claudia Chen, Yun Chon, Sandhia S Ponnarambil, Andrew Foster, Andrew W Lindsley, Christopher S Ambrose","doi":"10.1002/alr.70090","DOIUrl":"10.1002/alr.70090","url":null,"abstract":"<p><strong>Background: </strong>Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health-related quality of life and posing a safety hazard.</p><p><strong>Methods: </strong>WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Changes from baseline in biweekly mean Nasal Polyposis Symptom Diary (NPSD) loss of smell item, University of Pennsylvania Smell Identification Test (UPSIT), and 22-item Sino-Nasal Outcome Test (SNOT-22) loss of smell/taste item scores, as well as anosmia (UPSIT score ≤18) prevalence, were assessed over 52 weeks.</p><p><strong>Results: </strong>Among 408 patients (tezepelumab [n = 203]; placebo [n = 205]), significant improvements with tezepelumab versus placebo in NPSD loss of smell item, UPSIT, and SNOT-22 loss of smell/taste item scores were seen at week 4 (least-squares mean [LSM] treatment difference [95% CI]: -0.36 [-0.46, -0.27]; 6.03 [4.72, 7.34]; and -1.01 [-1.22, -0.80], respectively) and week 52 (-1.01 [-1.18, -0.83]; 9.50 [7.84, 11.16]; and -1.90 [-2.20, -1.61]); all nominal p < 0.0001. Between-treatment differences in daily NPSD loss of smell item score were evident from day 7 (LSM treatment difference: -0.08 [95% CI: -0.15, -0.02]; nominal p < 0.01). Improvements in NPSD loss of smell, UPSIT, and SNOT-22 loss of smell/taste item scores were observed across multiple prespecified subgroups. Anosmia prevalence was lower with tezepelumab than placebo at week 4 (43.0% [n/N = 64/149] vs. 80.3% [n/N = 106/132]) and week 52 (31.5% [n/N = 47/149] vs. 75.8% [n/N = 100/132]).</p><p><strong>Conclusions: </strong>Tezepelumab provides early and sustained improvements in sense of smell among patients with uncontrolled CRSwNP.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asthma Outcomes Following Early Versus Delayed Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps. 慢性鼻窦炎伴鼻息肉患者早期鼻窦手术与延迟鼻窦手术的哮喘结局。
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2025-12-30 DOI: 10.1002/alr.70091
Jamie R Oliver, Christopher L Crafton, Easton W Attwood, Nathan Farrokhian, Sanjeet Rangarajan, Jennifer A Villwock

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) often coexists with asthma. Endoscopic sinus surgery (ESS) improves asthma morbidity, but the impact of early surgery (< 6 months from diagnosis) versus later surgery (1-3 years) is unclear. We examined whether early ESS is associated with improved asthma outcomes compared with delayed surgery.

Methods: We conducted a retrospective cohort study using the TriNetX Research Network, including adults with CRSwNP who underwent ESS. Patients were grouped as early surgery (≤ 6 months after diagnosis) or late surgery (1-3 years). Outcomes over 5 years included asthma diagnoses by severity, exacerbations, and medication use (long-acting β2-agonists [LABA], corticosteroids, biologics). Propensity score matching was performed 1:1 (N = 3683 per group) based on demographics, baseline asthma severity, and asthma medication usage.

Results: After matching, groups were well balanced. Early ESS was associated with lower risk of moderate (11.5% vs. 13.5%; odds ratio [OR] = 0.84; p = 0.012) and severe persistent asthma (6.5% vs. 8.4%; OR = 0.76; p = 0.003). Rates of mild intermittent or persistent asthma and overall new asthma diagnoses did not differ. Early surgery patients had fewer associated asthma exacerbations (6.4% vs. 8.1%; OR = 0.78; p = 0.005) and were less likely to require LABAs (23.7% vs. 29.4%; OR = 0.75; p < 0.0001), steroids (63.7% vs. 67.4%; OR = 0.85; p = 0.0009), and biologics (7.7% vs. 10.1%; OR = 0.74; p = 0.0004).

Conclusion: Early ESS for CRSwNP is associated with reduced progression to moderate/severe asthma, fewer exacerbations, and lower reliance on oral steroids, LABAs, and biologics. These findings suggest early surgery may alter asthma trajectory and reduce treatment burden in CRSwNP patients.

背景:慢性鼻窦炎伴鼻息肉(CRSwNP)常与哮喘共存。内窥镜鼻窦手术(ESS)可改善哮喘发病率,但早期手术(诊断后< 6个月)与晚期手术(1-3年)的影响尚不清楚。我们研究了与延迟手术相比,早期ESS是否与哮喘预后改善有关。方法:我们使用TriNetX研究网络进行了一项回顾性队列研究,包括接受ESS治疗的CRSwNP成人。患者分为早期手术(诊断后≤6个月)和晚期手术(1-3年)两组。5年以上的结果包括哮喘诊断的严重程度、恶化情况和药物使用(长效β2激动剂[LABA]、皮质类固醇、生物制剂)。根据人口统计学、基线哮喘严重程度和哮喘药物使用情况进行1:1的倾向评分匹配(每组N = 3683)。结果:配对后,各组平衡良好。早期ESS与中度哮喘(11.5% vs. 13.5%;比值比[OR] = 0.84; p = 0.012)和重度持续性哮喘(6.5% vs. 8.4%; OR = 0.76; p = 0.003)的风险较低相关。轻度间歇性或持续性哮喘和总体新哮喘诊断的比率没有差异。早期手术患者的相关哮喘发作较少(6.4% vs. 8.1%; OR = 0.78; p = 0.005),需要LABAs (23.7% vs. 29.4%; OR = 0.75; p < 0.0001)、类固醇(63.7% vs. 67.4%; OR = 0.85; p = 0.0009)和生物制剂(7.7% vs. 10.1%; OR = 0.74; p = 0.0004)的可能性较小。结论:CRSwNP的早期ESS与中度/重度哮喘进展减少、恶化减少以及对口服类固醇、LABAs和生物制剂的依赖降低相关。这些发现表明,早期手术可能改变CRSwNP患者的哮喘发展轨迹并减轻治疗负担。
{"title":"Asthma Outcomes Following Early Versus Delayed Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps.","authors":"Jamie R Oliver, Christopher L Crafton, Easton W Attwood, Nathan Farrokhian, Sanjeet Rangarajan, Jennifer A Villwock","doi":"10.1002/alr.70091","DOIUrl":"https://doi.org/10.1002/alr.70091","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) often coexists with asthma. Endoscopic sinus surgery (ESS) improves asthma morbidity, but the impact of early surgery (< 6 months from diagnosis) versus later surgery (1-3 years) is unclear. We examined whether early ESS is associated with improved asthma outcomes compared with delayed surgery.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the TriNetX Research Network, including adults with CRSwNP who underwent ESS. Patients were grouped as early surgery (≤ 6 months after diagnosis) or late surgery (1-3 years). Outcomes over 5 years included asthma diagnoses by severity, exacerbations, and medication use (long-acting β2-agonists [LABA], corticosteroids, biologics). Propensity score matching was performed 1:1 (N = 3683 per group) based on demographics, baseline asthma severity, and asthma medication usage.</p><p><strong>Results: </strong>After matching, groups were well balanced. Early ESS was associated with lower risk of moderate (11.5% vs. 13.5%; odds ratio [OR] = 0.84; p = 0.012) and severe persistent asthma (6.5% vs. 8.4%; OR = 0.76; p = 0.003). Rates of mild intermittent or persistent asthma and overall new asthma diagnoses did not differ. Early surgery patients had fewer associated asthma exacerbations (6.4% vs. 8.1%; OR = 0.78; p = 0.005) and were less likely to require LABAs (23.7% vs. 29.4%; OR = 0.75; p < 0.0001), steroids (63.7% vs. 67.4%; OR = 0.85; p = 0.0009), and biologics (7.7% vs. 10.1%; OR = 0.74; p = 0.0004).</p><p><strong>Conclusion: </strong>Early ESS for CRSwNP is associated with reduced progression to moderate/severe asthma, fewer exacerbations, and lower reliance on oral steroids, LABAs, and biologics. These findings suggest early surgery may alter asthma trajectory and reduce treatment burden in CRSwNP patients.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145855625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence for Endoscopic Surveillance Post-Treatment for Nasopharyngeal Carcinoma: Detection of Recurrence and Osteoradionecrosis 鼻咽癌治疗后内镜监测的人工智能:复发和骨放射性坏死的检测。
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2025-12-20 DOI: 10.1002/alr.70089
Lirit Levi, Jeffrey D. Huynh, Yi Wang, Maxime Fieux, Mahdokht S. Manavi, Axel Renteria, Shiv K. Sethi, Noel Ayoub, Zara Patel, Jayakar V. Nayak, Peter Hwang, Michael T. Chang
{"title":"Artificial Intelligence for Endoscopic Surveillance Post-Treatment for Nasopharyngeal Carcinoma: Detection of Recurrence and Osteoradionecrosis","authors":"Lirit Levi,&nbsp;Jeffrey D. Huynh,&nbsp;Yi Wang,&nbsp;Maxime Fieux,&nbsp;Mahdokht S. Manavi,&nbsp;Axel Renteria,&nbsp;Shiv K. Sethi,&nbsp;Noel Ayoub,&nbsp;Zara Patel,&nbsp;Jayakar V. Nayak,&nbsp;Peter Hwang,&nbsp;Michael T. Chang","doi":"10.1002/alr.70089","DOIUrl":"10.1002/alr.70089","url":null,"abstract":"","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 2","pages":"205-208"},"PeriodicalIF":6.8,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory Effects of Microplastics and Nanoplastics on Nasal Airway Epithelial Cells. 微塑料和纳米塑料对鼻气道上皮细胞的炎症作用。
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2025-12-19 DOI: 10.1002/alr.70086
Maayan S Kahan, Hoang C B Nguyen, Pallavi Madhusudanan, Margaret B Mitchell, Di Huang, Benjamin S Bleier, Mansoor M Amiji, Alan D Workman

Background: Microplastics and nanoplastics (MNPs) have emerged as ubiquitous environmental contaminants; these particles have been detected in mucus and irrigation fluids, and at greater concentrations in patients with sinusitis and allergic rhinitis. Emerging evidence at other mucosal surfaces, including the gut and lung, suggests that MNPs exacerbate epithelial barrier dysfunction and induce inflammatory responses. Despite their relevance, the impact of inhaled plastics on the nasal epithelium, the initial point of contact for airborne plastics, remains underexplored.

Methods: Submerged RPMI 2650 nasal epithelial cultures and air-liquid interface (ALI) cultures of primary human nasal epithelial cells were dosed with polystyrene (PS) MNPs, with a focus on the effects of 100 nm nanoplastics and surface charge alterations. Analyses of secreted cytokines, transcriptomic changes, epithelial integrity, and histologic appearance were performed.

Results: Note that 100 nm PS nanoplastics caused transcriptomic inflammatory and oxidative stress pathway activation in RMPI 2650 submerged cultures, with conserved inflammatory gene signatures in the ALI exposure model as well. Dose-dependent elevations in IL-8 and TNFα were observed after ALI exposure to 1 µm PS microplastics, and 100 nm PS nanoplastics elicited early elevations in IL-6, IL-8, and TNF, with more pronounced effects from amine-modified particles, while no cytotoxicity, barrier disruption, or type-2 alarmin induction was observed. Scanning electron microscopy revealed ciliary disruption and particle adherence.

Conclusions: PS MNPs cause inflammatory cytokine responses in nasal epithelial cells over even a short timeframe, in addition to ciliary blunting and transcriptional evidence of significant inflammation and stress response. This sinonasal model can help answer critical questions about the pathogenicity of plastic exposures.

背景:微塑料和纳米塑料(MNPs)已成为无处不在的环境污染物;这些颗粒已在粘液和冲洗液中检测到,在鼻窦炎和过敏性鼻炎患者中浓度更高。包括肠和肺在内的其他粘膜表面的新证据表明,MNPs加剧上皮屏障功能障碍并诱导炎症反应。尽管它们具有相关性,但吸入塑料对鼻上皮(空气中塑料的初始接触点)的影响仍未得到充分研究。方法:用聚苯乙烯(PS) MNPs对RPMI 2650鼻上皮细胞和原代人鼻上皮细胞进行水浸培养和气液界面(ALI)培养,观察100 nm纳米塑料对其表面电荷变化的影响。分析分泌的细胞因子,转录组变化,上皮完整性和组织学外观。结果:值得注意的是,100 nm PS纳米塑料在RMPI 2650培养液中引起转录组炎症和氧化应激途径激活,在ALI暴露模型中也具有保守的炎症基因特征。在ALI暴露于1µm PS微塑料后,观察到IL-8和TNF - α的剂量依赖性升高,100 nm PS纳米塑料引起IL-6、IL-8和TNF的早期升高,胺修饰颗粒的影响更为明显,而没有观察到细胞毒性、屏障破坏或2型警报素诱导。扫描电镜显示纤毛断裂和颗粒粘附。结论:除了纤毛钝化和显著炎症和应激反应的转录证据外,PS MNPs甚至在短时间内引起鼻上皮细胞的炎症细胞因子反应。这个鼻腔模型可以帮助回答关于塑料接触致病性的关键问题。
{"title":"Inflammatory Effects of Microplastics and Nanoplastics on Nasal Airway Epithelial Cells.","authors":"Maayan S Kahan, Hoang C B Nguyen, Pallavi Madhusudanan, Margaret B Mitchell, Di Huang, Benjamin S Bleier, Mansoor M Amiji, Alan D Workman","doi":"10.1002/alr.70086","DOIUrl":"https://doi.org/10.1002/alr.70086","url":null,"abstract":"<p><strong>Background: </strong>Microplastics and nanoplastics (MNPs) have emerged as ubiquitous environmental contaminants; these particles have been detected in mucus and irrigation fluids, and at greater concentrations in patients with sinusitis and allergic rhinitis. Emerging evidence at other mucosal surfaces, including the gut and lung, suggests that MNPs exacerbate epithelial barrier dysfunction and induce inflammatory responses. Despite their relevance, the impact of inhaled plastics on the nasal epithelium, the initial point of contact for airborne plastics, remains underexplored.</p><p><strong>Methods: </strong>Submerged RPMI 2650 nasal epithelial cultures and air-liquid interface (ALI) cultures of primary human nasal epithelial cells were dosed with polystyrene (PS) MNPs, with a focus on the effects of 100 nm nanoplastics and surface charge alterations. Analyses of secreted cytokines, transcriptomic changes, epithelial integrity, and histologic appearance were performed.</p><p><strong>Results: </strong>Note that 100 nm PS nanoplastics caused transcriptomic inflammatory and oxidative stress pathway activation in RMPI 2650 submerged cultures, with conserved inflammatory gene signatures in the ALI exposure model as well. Dose-dependent elevations in IL-8 and TNFα were observed after ALI exposure to 1 µm PS microplastics, and 100 nm PS nanoplastics elicited early elevations in IL-6, IL-8, and TNF, with more pronounced effects from amine-modified particles, while no cytotoxicity, barrier disruption, or type-2 alarmin induction was observed. Scanning electron microscopy revealed ciliary disruption and particle adherence.</p><p><strong>Conclusions: </strong>PS MNPs cause inflammatory cytokine responses in nasal epithelial cells over even a short timeframe, in addition to ciliary blunting and transcriptional evidence of significant inflammation and stress response. This sinonasal model can help answer critical questions about the pathogenicity of plastic exposures.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI Versus CT in Acute Invasive Fungal Sinusitis: Mapping Diagnostic Accuracy Across Sinonasal Subsites 急性侵袭性真菌性鼻窦炎的MRI与CT对比:鼻窦亚位的诊断准确性。
IF 6.8 2区 医学 Q1 OTORHINOLARYNGOLOGY Pub Date : 2025-12-19 DOI: 10.1002/alr.70087
Shreya P. Ramkumar, Nirushan Narendran, Charles J. Gallego, Hasan Ozgur, Shireen Samargandy, Christopher H. Le
{"title":"MRI Versus CT in Acute Invasive Fungal Sinusitis: Mapping Diagnostic Accuracy Across Sinonasal Subsites","authors":"Shreya P. Ramkumar,&nbsp;Nirushan Narendran,&nbsp;Charles J. Gallego,&nbsp;Hasan Ozgur,&nbsp;Shireen Samargandy,&nbsp;Christopher H. Le","doi":"10.1002/alr.70087","DOIUrl":"10.1002/alr.70087","url":null,"abstract":"","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 2","pages":"201-204"},"PeriodicalIF":6.8,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Forum of Allergy & Rhinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1